ArticleThe journal of investigative dermatology. Symposium proceedings2011
Neurovascular and neuroimmune aspects in the pathophysiology of rosacea.
Article in The journal of investigative dermatology. Symposium proceedings, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06282679 (Clinical Observation of Intradermal Injections With Botulinum Toxin A in the Treatment of Rosacea Erythema Telangiectasia), which is not on this map. Cited by 116 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Observation of Intradermal Injections With Botulinum Toxin A in the Treatment of Rosacea Erythema Telangiectasia
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 293 citations in OpenAlex.
- Molecular Mechanisms in the Etiopathology of Rosacea-Systematic Review.International journal of molecular sciences · 2025Pooled it
- Association of rosacea with inflammatory bowel disease: A MOOSE-compliant meta-analysis.Medicine · 2019Pooled it
- Effect of combined probiotics and doxycycline therapy on the gut-skin axis in rosacea.mSystems · 2024Trial
- A Prospective Randomized Controlled Pilot Study to Assess the Response and Tolerability of Cold Atmospheric Plasma for Rosacea.Skin pharmacology and physiology · 2023Trial
- Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.The British journal of dermatology · 2012Trial
- From Genetic Variants to Immune Dysregulation: Multi-Omics Mendelian Randomization Decodes Molecular Networks in Rosacea.Annals of dermatology · 2026Article
- Gut-Skin Axis Revisited: A Nationwide Cohort Study on the Bi-directional Relationship Between Rosacea and Irritable Bowel Syndrome.Annals of dermatology · 2026Article
- Rosacea in Patients with Skin of Color: Diagnosis and Management.American journal of clinical dermatology · 2026Review
- Neurogenic Rosacea and Facial Dysesthesia: Neurovascular-Immune Mechanisms and Translational Therapeutic Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Targeting skin barrier repair: mechanisms of action, therapeutic evidence, and clinical translation challenges of mesenchymal stem cell-derived exosomes.Stem cell research & therapy · 2026Review
- An Attempt to Establish the Consensus Regarding the Diagnosis, Classification, and Treatment of Rosacea in Japan Using a Modified Delphi Method: The Japan Rosacea Consensus.The Journal of dermatology · 2026Article
- MRGPRX2 as a novel therapeutic target in headache.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Imperatorin Mitigates Rosacea-Like Inflammation by Modulating the Crosstalk Between JNK1 and STAT1.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Revisiting Rosacea Through the Skin-Gut-Brain Axis: A Neuroimmune Perspective.Life (Basel, Switzerland) · 2026Review
- Transcriptomic and metabolomic insights into gabapentin's therapeutic role in neurogenic inflammation of rosacea.Communications biology · 2026Article
- Formulation and Biological Evaluation ofAntioxidants (Basel, Switzerland) · 2026Article
- Systemic Inflammatory and Oxidative-Metabolic Alterations in Rosacea: A Cross-Sectional Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
- Lithospermic acid, a novel KLK5 inhibitor, ameliorates rosacea by suppressing the TLR4/NF-κB signaling pathway and rectifying phenylalanine metabolism.Frontiers in immunology · 2026Article
- Targeting Macrophage-to-Myofibroblast Transition Mitigates Progression from Inflammation to Fibrosis in Rosacea.International journal of biological sciences · 2026Article
- Cutaneous lymphatics and skin diseases: mechanisms, imaging modalities, and future therapeutic strategies.Frontiers in physiology · 2026Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
Rosacea is a common skin disease with a high impact on quality of life. Characterized by erythema, edema, burning pain, immune infiltration, and facial skin fibrosis, rosacea has all the characteristics of neurogenic inflammation, a condition induced by sensory nerves via antidromically released neuromediators. To investigate the hypothesis of a central role of neural interactions in the pathophysiology, we analyzed molecular and morphological characteristics in the different subtypes of rosacea by immunohistochemistry, double immunofluorescence, morphometry, real-time PCR, and gene array analysis, and compared the findings with those for lupus erythematosus or healthy skin. Our results showed significantly dilated blood and lymphatic vessels. Signs of angiogenesis were only evident in phymatous rosacea. The number of mast cells and fibroblasts was increased in rosacea, already in subtypes in which fibrosis is not clinically apparent, indicating early activation. Sensory nerves were closely associated with blood vessels and mast cells, and were increased in erythematous rosacea. Gene array studies and qRT-PCR confirmed upregulation of genes involved in vasoregulation and neurogenic inflammation. Thus, dysregulation of mediators and receptors implicated in neurovascular and neuroimmune communication may be crucial at early stages of rosacea. Drugs that function on neurovascular and/or neuroimmune communication may be beneficial for the treatment of rosacea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.